Back to Journals » OncoTargets and Therapy » Volume 9

Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis


Authors Liu Y, Wang X, Wang Y, HU X, Yan J, Zhang Y, Wang W, Yang R, Feng Y, Gao S, Feng X

Received 16 December 2015

Accepted for publication 9 March 2016

Published 4 May 2016 Volume 2016:9 Pages 2649—2654

DOI https://doi.org/10.2147/OTT.S102616

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Narasimha Reddy Parine

Peer reviewer comments 3

Editor who approved publication: Dr William Cho


Yong-Xuan Liu, Xin-Shuai Wang, Yu-Feng Wang, Xiao-Chen Hu, Jun-Qiang Yan, Ya-Li Zhang, Wei Wang, Rui-Jie Yang, Ying-Ying Feng, She-Gan Gao, Xiao-Shan Feng

Department of Oncology, Cancer Institute, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, People’s Republic of China

Abstract: The overexpression of programmed cell death-ligand 1(PD-L1) has been observed in gastric cancer (GC). However, whether the expression of PD-L1 in tumor cells or blood serum is associated with the prognosis of patients with GC remains unclear. Therefore, we performed a meta-analysis to evaluate the prognostic significance of PD-L1 expression in GC. Electronic databases were searched systematically. Studies that met the inclusion criteria were included in the meta-analysis. Data concerning the hazard ratio (HR) for overall survival and disease-free survival with a 95% confidence interval (CI) according to the expression status of PD-L1 evaluated by immunohistochemistry or enzyme-linked immunosorbent assay were extracted. The data were analyzed using a random effects model. Subgroup analyses were proposed. Our results showed that eight studies with 950 patients met the inclusion criteria and were included in the meta-analysis. The pooled HR for overall survival indicated that patients with PD-L1-positive expression had significantly shorter survival time compared with the PD-L1-negative group (HR 1.60, 95% CI 1.09–2.36, P=0.012). The pooled HR for disease-free survival demonstrated that the difference between the two groups was not statistically significant (HR 1.02, 95% CI 0.32–3.20, P=0.98). In conclusion, our results indicate that the evaluation of PD-L1 overexpression in GC tissue or blood serum may be useful in the future as a novel prognostic factor.

Keywords: PD-L1, gastric cancer, prognostic, meta-analysis, OS, immunohistochemistry

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]